Newland Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Newland Pharmaceutical has been growing earnings at an average annual rate of 11.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 11.1% per year. Newland Pharmaceutical's return on equity is 10.8%, and it has net margins of 23.5%.
Key information
11.4%
Earnings growth rate
-10.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 11.1% |
| Return on equity | 10.8% |
| Net Margin | 23.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Newland Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 699 | 164 | 42 | 61 |
| 30 Jun 24 | 714 | 177 | 46 | 60 |
| 31 Mar 24 | 663 | 168 | 44 | 56 |
| 31 Dec 23 | 651 | 159 | 41 | 52 |
| 30 Sep 23 | 669 | 180 | 46 | 39 |
| 30 Jun 23 | 614 | 154 | 38 | 36 |
| 31 Mar 23 | 639 | 145 | 40 | 34 |
| 01 Jan 23 | 627 | 132 | 41 | 30 |
| 30 Sep 22 | 635 | 127 | 68 | 41 |
| 30 Jun 22 | 602 | 120 | 46 | 21 |
| 31 Mar 22 | 545 | 116 | 44 | 19 |
| 01 Jan 22 | 514 | 115 | 43 | 21 |
| 31 Dec 20 | 433 | 118 | 28 | 21 |
| 31 Dec 19 | 407 | 109 | 26 | 17 |
| 31 Dec 18 | 295 | 29 | 27 | 10 |
Quality Earnings: 301277 has high quality earnings.
Growing Profit Margin: 301277's current net profit margins (23.5%) are lower than last year (26.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301277's earnings have grown by 11.4% per year over the past 5 years.
Accelerating Growth: 301277's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301277 had negative earnings growth (-8.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 301277's Return on Equity (10.8%) is considered low.